Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

Management of type 1 diabetes mellitus 

Management of type 1 diabetes mellitus
Chapter:
Management of type 1 diabetes mellitus
Author(s):

Simon R. Heller

DOI:
10.1093/med/9780199235292.003.1420
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 October 2021

Almost 90 years after the discovery of insulin, people with type 1 diabetes still use subcutaneous insulin to manage their condition. Such treatment is life saving, preventing early death from ketoacidosis, relieving symptoms, and reversing most of the pathophysiological features within a few weeks of diagnosis. Yet people with diabetes still die prematurely from long-term complications, and the quality of the lives of others is blighted by impaired vision, amputation, renal replacement therapy, or recurrent hypoglycaemia. Despite the clear demonstration that tight glycaemic control can delay, and perhaps prevent, both micro- and macro-vascular disease, the limitations of current therapy prevent most from achieving these levels of blood glucose control. There is now a realistic, albeit distant, prospect of a revolution in treatment, involving either cell therapy (see Chapters 13.10 and 13.11) or closed-loop technology combining continuous glucose sensing and insulin-infusion pumps (see Chapter 13.4.9.2). However, for the foreseeable future, the responsibility of the diabetes professional is to assist individuals with type 1 diabetes to achieve both an optimum level of blood glucose and quality of life with best use of available methods.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.